Fulcrum therapeutics announces topline results from phase 3 reach clinical trial of losmapimod in facioscapulohumeral muscular dystrophy (fshd)

― losmapimod failed to show an improvement in relative surface area (rsa), a measure of reachable workspace (rws), versus placebo at week 48 ―

FULC Ratings Summary

FULC Quant Ranking